Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EHA 2023 | Improving eligibility for treatment-free remission in CML

Massimo Breccia • 13 Jun 2023
EHA 2023
Chronic Myeloid Leukemia Leukemia Asciminib Dasatinib Nilotinib
DASISION SUSTRENIM

Massimo Breccia, MD, Sapienza University of Rome, Rome, Italy, discusses the important goal of treatment-free remission (TFR) in chronic myeloid leukemia, commenting on strategies to increase patient eligibility for TFR, such as early tyrosine kinase inhibitor (TKI) switch, combinatorial strategies, TKI de-escalation strategies, and using novel TKIs like asciminib. This interview took place at the 28th Congress of the European Hematology Association (EHA) 2023 in Frankfurt, Germany.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

Disclosures

Honoraria by Novartis, BMS, Incyte, Pfizer, AOP, Abbvie

More from Massimo Breccia

1:34
Long-term follow-up from the OITI trial: ponatinib in patients with CML in Italy
Massimo Breccia • 13 Jun 2023

Related Videos

1:40
The role of CPX-351 in the AML treatment landscape & insights into the AMLSG 30-18 trial
Felicitas Thol • 19 Apr 2024
3:21
Integrating genomics and MRD in transplant decision-making for patients with AML
Jurjen Versluis • 22 Apr 2024
4:19
Blinatumomab to achieve remission and consolidation with haploSCT for pediatric ALL
Alberto Olaya-Vargas • 15 Apr 2024
3:32
Improving CAR-T therapy for ALL & lymphoma: allogeneic products & reducing CRS/ICANS
Sridhar Chaganti • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals